Published online Jan 28, 2023. doi: 10.4329/wjr.v15.i1.20
Peer-review started: July 5, 2022
First decision: September 5, 2022
Revised: September 15, 2022
Accepted: December 13, 2022
Article in press: December 13, 2022
Published online: January 28, 2023
Processing time: 195 Days and 19.3 Hours
Increased use of functional magnetic resonance imaging (MRI) methods such as diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI consisting of sequential contrast series, allows us to obtain more information on the microstructure, cellularity, interstitial distance, and vascularity of tumors, which has increased the discrimination power for benign and malignant salivary gland tumors (SGTs). In the last few years, quantitative DCE MRI data containing T1 perfusion parameters (Ktrans, Kep and Ve), were reported to contribute to the differentiation of benign or malignant subtypes in SGTs.
To evaluate the diagnostic efficacy of DWI and semiquantitative and quantitative perfusion MRI parameters in SGTs.
Diffusion MRI [apparent diffusion coefficient (ADC) value] with a 1.5 T MR machine, semiquantitative perfusion MRI [time intensity curve (TIC) pattern], and quantitative perfusion MRI examinations (Ktrans, Kep and Ve) of 73 tumors in 67 patients with histopathological diagnosis performed from 2017 to 2021 were retrospectively evaluated. In the ADC value and semiquantitative perfusion MRI measurements, cystic components of the tumors were not considered, and the region of interest (ROI) was manually placed through the widest axial section of the tumor. TIC patterns were divided into four groups: Type A = Tpeak > 120 s; type B = Tpeak ≤ 120 s, washout ratio (WR) ≥ 30%; type C = Tpeak ≤ 120 s, WR < 30%; and type D = flat TIC. For the quantitative perfusion MRI analysis, a 3D ROI was placed in the largest solid component of the tumor, and the Ktrans, Kep and Ve values were automatically generated.
The majority of SGTs were located in the parotid glands (86.3%). Of all the SGTs, 68.5% were benign and 31.5% were malignant. Significant differences were found for ADC values among pleomorphic adenomas (PMAs), Warthin's tumors (WTs), and malignant tumors (MTs) (P < 0.001). PMAs had type A and WTs had type B TIC pattern while the vast majority of MTs and other benign tumors (OBTs) (54.5% and 45.5%, respectively) displayed type C TIC pattern. PMAs showed no washout, while the highest mean WR was observed in WTs (59% ± 11%). Ktrans values of PMAs, WTs, OBTs, and MTs were not significantly different. Kep values of PMAs and WTs were significantly different from those of OBTs and MTs. Mean Ve value of WTs was significantly different from those of PMAs, OBTs, and MTs (P < 0.001).
The use of quantitative DCE parameters along with diffusion MRI and semiquantitative contrast-enhanced MRI in SGTs could improve the diagnostic accuracy.
Core Tip: In this study, the diagnostic features of diffusion-weighted imaging and semiquantitative and quantitative perfusion magnetic resonance imaging (MRI) parameters were evaluated in salivary gland tumors. The apparent diffusion coefficient (ADC) values of pleomorphic adenomas (PMAs) were significantly higher than those of Warthin's tumors (WTs), other benign tumors (OBTs), and malignant tumors (MTs). On semiquantitative MRI, PMAs were distinguished from all other tumors by their long Tpeak times and lack of washout. WTs had the shortest Tpeak and highest washout ratio values. For quantitative perfusion MRI parameters, the Kep value of WTs was significantly higher than those of other tumors. The Ve values of WTs and OBTs differed significantly from those of PMAs and MTs.
- Citation: Gökçe E, Beyhan M. Diagnostic efficacy of diffusion-weighted imaging and semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging in salivary gland tumors. World J Radiol 2023; 15(1): 20-31
- URL: https://www.wjgnet.com/1949-8470/full/v15/i1/20.htm
- DOI: https://dx.doi.org/10.4329/wjr.v15.i1.20
Salivary gland tumors (SGTs) account for about 2.0%-6.5% of all head and neck tumors. Approximately 70% of them originate from the parotid glands, and a small number have submandibular, sublingual, and minor salivary gland origins. While the majority of tumors from the parotid glands are benign, malignancies are more common in those located in other glands. Preoperative characterization of SGTs is important for treatment planning. The choice of surgery method for SGTs is closely associated with the histology of the tumor. Diagnosis is mostly based on combined evaluation of clinical features and findings from physical examinations, imaging and cytological observations. Fine-needle aspiration biopsy (FNAB) is the most commonly used method for cytological examinations but complex pathologies can result in false positives and false negatives in malignant tumors (MTs)[1,2]. Conventional magnetic resonance imaging (MRI) is very useful for identifying the tumor location, morphology, extension, and its association with the nerves and inner structure[1-3]. However, diagnosing MTs and benign tumors (BTs) by conventional MRI can be difficult due to overlapping findings[1,2,4]. In recent years, an increase has been reported in diagnostic accuracy in SGTs for distinguishing between MTs and BTs with the use of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI techniques[1,5-9]. DCE MRI is used to track an exogenous, paramagnetic contrast agent in tissues and has been a powerful tool in the characterization of tumor hemodynamics[1,3,10,11]. As a semiquantitative method in DCE MRI, patterns have been established by measuring time to peak (Tpeak) and washout ratio (WR) on the time intensity curve (TIC)[1,3]. Tpeak is closely related to microvessel count while WR reflects the stromal cellularity grade. On quantitative DCE MRI, on the other hand, perfusion parameters such as Ktrans [volume transfer constant between blood plasma and the extracellular extravascular space (EES)], Kep (flux rate constant between the EES and plasma), and Ve (EES fractional volume) are used[1,3]. Although there are many studies dealing with diffusion and semiquantitative DCE MRIs in SGTs, the number of quantitative MRI studies is limited[12-15]. In the present study, the diagnostic value of diffusion MRI and semiquantitative and quantitative perfusion MRI parameters was evaluated in SGTs.
The study was conducted retrospectively following approval by the local ethics committee (20-KAEK-105). A total of 67 patients with tumors originating from or involving the salivary glands were included. The study included patients who had swelling of the face or in the salivary glands, who were subjected to MRI, diffusion MRI, and perfusion MRI examinations at our hospital between April 2017 and February 2021 and who were diagnosed histopathologically after FNAB, Tru-cut biopsy, or surgical removal. For this study, patients whose neck and maxillofacial MRI examination reports included the description of a mass in the salivary glands were surveyed in picture archiving and communication systems. A total of 33 patients were excluded: 2 patients with intra-lesion hemorrhage due to FNAB before the MRI examination, 16 patients who had contrast-enhanced MRI but did not have perfusion MRI series, and 15 patients whose diagnosis was not confirmed histopathologically. Thus, a total of 73 MTs and BTs, which originated from major and minor salivary glands in 67 patients, were included in the study (Figure 1).
MRI was performed on a 1.5 T superconducting MRI system [General Electric (GE) Signa Explorer Software Version 25; GE Healthcare, Milwaukee, WI, United States, 2016] with head and neck array coils. Routine MRI sequences included axial T1-weighted [time to repetition/time to echo (TR/TE), 456 ms/8.1 ms], in phase axial T2-weighted (TR/TE, 3711 ms/82.8 ms), sagittal T2-weighted (TR/TE, 4499 ms/88.2 ms), and coronal T2-weighted (TR/TE, 4380 ms/84.6 ms). DCE MRI was performed with a T1-weighted 3D fast spoiled gradient echo sequence [TR/TE/time to inversion, 3.8 ms/1.3 ms/15 ms; flip angle, 20°]. The contrast agent Gd-DTPA (Dotarem, Guerbet, France) was injected after the fourth dynamic sequence acquisition at a rate of 2.0 mL/s via the right antecubital vein. The contrast agent was administered at a dose of 0.2 mmoL/kg body weight. Immediately after the injection of the contrast agent, a 20 mL saline flush was carried out at the same injection rate. In total, 18-21 dynamic sequence acquisitions with 30 dynamic images per sequence were performed with total scanning time ranging from 3 min and 11 s to 5 min and 24 s. The location, morphology, and internal structure of the tumor were evaluated by conventional MRI (Figures 2A and B, 3A and B, 4A and B, 5A and B).
DWI was performed using a multislice echo-planar single-shot spin-echo sequence, on the axial plane (TR/TE = 5476 ms/95.4 ms, field of view = 26 cm, matrix = 96 × 128, section thickness = 4-5 mm, and interslice gap = 4 mm). Three diffusion gradients were applied sequentially in the x, y, and z directions with b values of 0 and 1000 s/mm2 (Figure 2B). The acquisition time varied from 60 s to 120 s. The apparent diffusion coefficient (ADC) maps were generated automatically.
"GE Advantage Windows Workstation 4.7" was used to determine ADC values on diffusion MRI and to perform measurements in semiquantitative and quantitative perfusion MRI. Image analysis and region of interest (ROI) measurements were carried out on a consensus basis by two neuroradiologists (Erkan Gökçe and Murat Beyhan with more than 12 and 7 years of work experience, respectively) who were not aware of the clinical status of the patients. On ADC value measurements, cystic components of the tumors were not considered, the ROI was manually placed through the widest axial section of the tumor, and the ADC value was determined as mm2/s (Figures 2C, 3C, 4C and 5C). Semiquantitative analysis of DCE MRI was based on TIC (Figures 2D and E, 3D and E, 4D and E, 5D and E). Tpeak was measured as the time from the point where the lesion began to show contrast enhancement to the point with the highest level of contrast enhancement. TICs were evaluated in four different categories based on Yabuuchi et al[10]: Type A = Tpeak > 120 s; type B = Tpeak ≤ 120 s, WR ≥ 30%; type C = Tpeak ≤ 120 s, WR < 30%; and type D = flat TIC. To confirm the accuracy of TIC and perfusion biomarker analyses, ROIs were drawn in a way to avoid the vascular and cystic parts of the tumors. Quantitative perfusion DCE MRI parameters were measured using the Tofts kinetic model[16]. For quantitative perfusion MRI analysis, a 3D ROI was placed in the largest solid component of the tumor, and the Ktrans, Kep and Ve values were generated automatically(Figures 2F-H, 3F-H, 4F-H, 5F-H).
Statistical analyses were performed using SPSS 18.0 software (IBM, Chicago, IL, United States) and MedCalc statistical software version 20.009 (MedCalc software bvba, Ostend, Belgium). For each parameter, the conformity of the groups to the normal distribution was evaluated by the Shapiro-Wilk test, and the Levene test was used to evaluate the homogeneity of variances. Data are expressed as the mean ± SD or frequency and percent. One-way ANOVA was used for the groups with a normal distribution for comparison of the groups, and Bonferroni correction was applied in multiple comparisons. The Kruskal-Wallis test was used to compare the groups that did not fit the normal distribution, and Bonferroni correction was applied in multiple comparisons. The area under curve (AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and cut-off values of diagnostic parameters were calculated for each tumor group by performing receiver operating characteristic curve (ROC) analysis.
The age range of the 67 patients (40 male and 27 female) included in the study was 12-93 years (mean age = 56.9 ± 15.8 years). One patient had three lesions in the salivary glands, while four patients had two and the remaining 62 had one lesion. Thus, 73 lesions in 67 patients were evaluated. The majority of the lesions (86.3%) were located in the parotid glands, while a small number (4.1%) originated from minor salivary glands. The locations, numbers, and frequencies of SGTs are shown in Table 1. Approximately two-thirds of the lesions (68.5%) were benign (Figures 2 and 3), and one-third (31.5%) was malignant (Figures 4 and 5). Warthin's tumors (WTs) (36.0%) were the most common BTs, followed by pleomorphic adenomas (PMAs) (28.0%). Of the MTs, squamous cell cancer (47.8%), adenoid cystic cancers (13.0%), and malignant lymphomas (13.0%) were the most common. The numbers of benign and malignant SGTs are provided in Table 2. The ADC values of PMAs were significantly higher than those of WTs, other benign tumors (OBTs), and MTs (P < 0.001). However, there was no significant difference in ADC values for OBTs, WTs, and MTs. Significant differences were not found for ADC values of all BTs and MTs. The mean ADC values of SGTs are shown in Table 3.
Location | n (%) |
Unilateral parotid gland | 61 (83.6) |
Submandibular gland | 6 (8.2) |
Minor salivary gland | 3 (4.1) |
Bilateral parotid gland | 2 (2.7) |
Sublingual gland | 1 (1.4) |
Benign SGTs | n (%) | Malignant SGTs | n (%) |
Warthin’s tumor | 18 (24.7) | Squamous cell carcinoma | 11 (15.1) |
Pleomorphic adenoma | 14 (19.2) | Adenoid cystic carcinoma | 3 (4.1) |
Inflammatory process | 12 (16.4) | Malignant lymphoma | 3 (4.1) |
Lipoma | 4 (5.5) | Adenocarcinoma | 1 (1.4) |
Benign cystic lesions | 1 (1.4) | Mucoepidermoid carcinoma | 1 (1.4) |
Carcinoma ex pleomorphic adenoma | 1 (1.4) | ||
Other benign lesions | 1 (1.4) | Acinic cell carcinoma | 1 (1.4) |
Follicular dendritic cell sarcoma | 1 (1.4) | ||
Salivary duct carcinoma | 1 (1.4) | ||
Total | 50 (68.5) | 23 (31.5) |
Pleomorphic adenoma | Warthin’s tumor | Other benign tumors | Malignant tumors | P value | |
ADC (× 10−3 mm2/s) | 1.61 ± 0.26 (a) | 0.72 ± 0.09 (b) | 0.77 ± 0.19 (b) | 0.96 ± 0.33 (b) | < 0.001 |
Ktrans (min−1) | 0.42 ± 0.35 | 0.75 ± 0.55 | 0.57 ± 0.37 | 0.77 ± 0.56 | 0.131 |
Kep (min−1) | 0.69 ± 0.33 (a) | 6.2 ± 3.13 (b) | 1.95 ± 0.94 (c) | 1.72 ± 0.92 (c) | < 0.001 |
Ve | 0.65 ± 0.25 (a) | 0.11 ± 0.04 (b) | 0.3 ± 0.12 (c) | 0.48 ± 0.24 (ac) | < 0.001 |
An evaluation of Tpeak values of semiquantitative perfusion MRI parameters revealed that PMAs reached Tpeak significantly later (mean Tpeak = 202.74 ± 21.48 s) than WTs, OBTs, and MTs while the difference between OBTs and MTs for Tpeak values was not significant. WTs reached Tpeak significantly earlier than other tumors. With regard to WR, no washout was observed in PMAs. WTs had the highest mean WR value (59% ± 11%), which was significantly different from the mean WR values of MTs and OBTs. PMAs had type A and WTs had type B TIC pattern, while the majority of MTs and OBTs (54.5% and 45.5%, respectively) exhibited type C TIC pattern. Semiquantitative DCE MRI parameters of SGTs are provided in Table 4.
TIC Pattern, n(%) | Tpeak (s) | WR (%) | ||||
A | B | C | D | |||
Pleomorphic adenomas | 14 (70.0) | 0 (0) | 0 (0) | 0 (0) | 202.74 ± 21.48 (a) | - |
Warthin’s tumors | 0 (0) | 18 (66.7) | 0 (0) | 0 (0) | 20.26 ± 11.72 (b) | 59.33 ± 10.99 (a) |
Other benign tumors | 4 (20.0) | 4 (14.8) | 10 (45.5) | 0 (0) | 74.94 ± 75.47 (c) | 17.89 ± 14.99 (b) |
Malignant tumors | 2 (10.0) | 5 (18.5) | 12 (54.5) | 4 (100) | 60.60 ± 55.78 (c) | 18.48 ± 18.38 (b) |
P value | < 0.001 | < 0.001 | < 0.001 |
For quantitative perfusion MRI parameters, Ktrans values of PMAs, WTs, OBTs, and MTs were not significantly different. The Kep value of WTs, on the other hand, was significantly higher than those of other tumors (P < 0.001). For Ve value, WTs and OBTs differed significantly from PMAs and MTs (P < 0.001). An evaluation of all BTs and MTs showed significant differences for Kep and Ve values (P < 0.05) but not for Ktrans values. Quantitative DCE MRI parameters of SGTs are shown in Table 3.
The results of ROC analysis and cut-off values used for the parameters of DWI, semiquantitative and quantitative MRI of PMAs, WTs, and malignant SGTs are given in Table 5.
Variable | Cut-off | AUC (95% CI) | Sensitivity | Specificity | PPV | NPV | P value |
Pleomorphic adenomas | |||||||
ADC value | > 1.1 | 0.977 (0.911-0.998) | 1.000 | 0.898 | 0.700 | 1.000 | < 0.001 |
Tpeak | > 120 | 0.947 (0.868-0.986) | 1.000 | 0.898 | 0.700 | 1.000 | < 0.001 |
Ktrans | ≤ 0.46 | 0.702 (0.584-0.804) | 0.857 | 0.627 | 0.353 | 0.949 | 0.005 |
Kep | ≤ 1.14 | 0.926 (0.840-0.974) | 0.929 | 0.831 | 0.565 | 0.980 | < 0.001 |
Ve | ≥ 0.4 | 0.849 (0.746-0.922) | 0.929 | 0.729 | 0.448 | 0.977 | < 0.001 |
Warthin’s tumors | |||||||
ADC value | ≤ 0.8 | 0.742 (0.626-0.837) | 0.944 | 0.582 | 0.425 | 0.970 | < 0.001 |
Tpeak | ≤ 19.1 | 0.869 (0.769-0.936) | 0.667 | 0.909 | 0.706 | 0.893 | < 0.001 |
WR | > 43 | 0.981 (0.917-0.999) | 0.944 | 0.909 | 0.773 | 0.980 | < 0.001 |
Ktrans | > 0.3 | 0.577 (0.455-0.692) | 0.889 | 0.346 | 0.308 | 0.905 | 0.291 |
Kep | > 2.44 | 0.973 (0.905-0.997) | 1.000 | 0.855 | 0.692 | 1.000 | < 0.001 |
Ve | ≤ 0.17 | 0.958 (0.883-0.991) | 1.000 | 0.909 | 0.783 | 1.000 | < 0.001 |
Malignant tumors | |||||||
ADC value | > 0.7 | 0.541 (0.420-0.658) | 0.783 | 0.440 | 0.391 | 0.815 | 0.569 |
Tpeak | ≤ 120 | 0.531 (0.410-0.649) | 0.913 | 0.360 | 0.396 | 0.900 | 0.648 |
WR | ≤ 49 | 0.562 (0.441-0.678) | 1.000 | 0.300 | 0.397 | 1.000 | 0.351 |
Ktrans | > 0.53 | 0.599 (0.477-0.712) | 0.652 | 0.600 | 0.429 | 0.789 | 0.194 |
Kep | ≤ 3.7 | 0.592 (0.471-0.706) | 1.000 | 0.300 | 0.397 | 1.000 | 0.160 |
Ve | > 0.35 | 0.702 (0.584-0.804) | 0.696 | 0.660 | 0.485 | 0.825 | 0.001 |
In recent years, diffusion MRI has been an essential complement to conventional sequences in the radiological evaluation of SGTs[1,3,6-10,13-15,17,18]. Diffusion MRI allows us to evaluate the cellularity in tissues and the changes that physiological processes create on microstructural features. As malignant or benign SGTs include a highly heterogeneous group, their ADC values could also be highly variable. In cell-rich tumors such as WT and lymphoma, ADC values are low, but tumors containing heterogeneous components such as PMA have higher ADC values[1,13]. In many DWI studies involving SGTs, ADC values were reported to be useful in distinguishing BTs and MTs[6-8,17,19-21]. However, there are also studies reporting that DWI was not sufficient to make this distinction but ADC values could be useful in distinguishing some subtypes of MTs or BTs[10,22-24]. An evaluation of mean ADC values of all BTs and MTs in the present study showed that ADC values of BTs (0.98 × 10-3 ± 0.43 mm2/s) and MTs (0.95 × 10-3 ± 0.31 mm2/s) were similar and did not differ significantly. However, when specific tumoral subgroups were evaluated, significant differences were found in the mean ADC values among PMAs, WTs, and MTs (P < 0.001). In a ROC analysis using an ADC cut-off value of > 1.1 × 10-3 mm2/s for PMAs, the AUC, sensitivity, and specificity were 97.7%, 100%, and 89.8%, respectively. A ROC analysis of WTs using an ADC cut-off value of ≤ 0.8 × 10-3 mm2/s, on the other hand, resulted in AUC, sensitivity, and specificity values of 74.2%, 94.4%, and 58.2%, respectively. These values were 54.1%, 78.3%, and 44.0%, respectively, for MTs with an ADC cut-off value of > 0.7 × 10-3 mm2/s. In the present study, the mean ADC value of malignant lymphomas was 0.56 × 10-3 ± 0.05 mm2/s, which was well below the average ADC value of all MTs. This finding indicated that diffusion MRI could be more useful in distinguishing the subgroups within both BTs and MTs than contributing to a more general distinction between MTs and BTs.
In addition to diffusion MRI, the parameters of semiquantitative DCE MRI (TIC patterns) have also been frequently used in recent years for the differential diagnosis of SGTs[9,12,20,25,26]. On DCE MRI, TIC is obtained from signal intensity changes before the contrast agent administration, during the transition of contrast agent from the capillary bed to extravascular-intercellular distance, and during the washing of contrast agent from the tissue[1,18]. TIC patterns are correlated with tumor cellularity and vascularity[1,5,18,27]. PMAs have progressive contrast-enhancement due to low microvessel count and cellularity-stromal grade, and their washout patterns are mostly negative and, to a lesser degree, in the form of a plateau[1,27]. In the present study, type A TIC pattern (curve pattern with progression towards the late phases) was observed in all PMAs. Tpeak values ranged from 161.80 s to 251.70 s. The average Tpeak value of PMAs (202.74 ± 21.48 s) was significantly longer compared to the Tpeak values of all other SGTs. In ROC analysis of PMAs using a cut-off value of Tpeak > 120 s, AUC, sensitivity, specificity, PPV, and NPV were 94.7%, 100%, 89.8%, 70.0%, and 100%, respectively. WTs feature rapid contrast enhancement and washout due to their high microvessel count and cellularity-stromal grade. In the present study, type B TIC pattern (Tpeak ≤ 120 s, WR ≥ 30%) was observed in all WTs. Tpeak values ranged from 10.80 s to 46.40 s, while WR varied from 31% to 75%. The mean Tpeak of WTs (20.26 ± 11.72 s) was significantly shorter than that of other parotid lesions. The average WR value of WTs (59.33% ± 10.99%) was significantly higher than that of any other tumors. In ROC analysis of WTs using a cut-off value of WR > 43%, AUC, specificity, and PPV were quite high (98.1%, 94.4%, and 90.9%, respectively). Due to their high microvessel count and lower cellularity-stromal grade, MTs have rapid enhancement but their washouts tend to be slower than those of WTs[1,27]. In the present study, the mean Tpeak value of MTs (60.60 ± 55.78 s) was significantly shorter than the Tpeak value of PMAs. The mean WR value of MTs (18.48 ± 18.38%) was significantly lower than that of WTs, but was not different from the mean WR value of OBTs. In ROC analysis of MTs with cut-off values of Tpeak ≤ 120 s and WR ≤ 49%, sensitivities were quite high (91.3% and 100%, respectively) but specificities were quite low (36.0% and 30.0%, respectively). A survey of semiquantitative DCE MRI studies in the literature showed that PMAs generally had type A pattern, while WTs had type B and MTs had type C TIC patterns[4,5,26]. TIC patterns are considered to have a higher diagnostic accuracy in distinguishing subgroups in SGTs compared to their power to distinguish all BTs from MTs. However, it was mentioned that TIC patterns had higher specificity especially in PMAs and WTs while their specificity in MTs was lower[4,18,25,26]. In their study with all SGTs, Lam et al[26] showed that all MTs except lymphomas showed type C TIC pattern (Tpeak < 150 s and WR < 30%), while 70% of lymphomas had type B TIC pattern (Tpeak < 150 s and WR ≥ 30%). Similar to the findings of Lam et al[26], 66.7% of lymphomas in the present study showed type B TIC pattern. However, unlike their findings, some other MTs showed types A, B, and D TIC patterns. There are also studies in the literature reporting that all WTs had type B TIC pattern[4,10,12]. In accordance with their findings, 100% of WTs in the present study featured type B TIC pattern. Subtypes of SGTs in the present study generally had similar TIC patterns to those reported in the literature.
The literature contains several studies on quantitative DCE perfusion MRI parameters (Ktrans, Kep, and Ve) in SGTs[3,14,15,28]. In these studies, mean Ktrans values for PMAs ranged from 0.101 ± 0.069 min−1 to 0.217 ± 0.036 min−1, mean Kep values from 0.245 ± 0.160 min−1 to 0.567 ± 0.048 min−1, and mean Ve values from 0.360 to 0.590 ± 0.478, while mean Ktrans values for WTs varied between 0.105 min−1 ± 0.064 min−1 and 0.464 ± 0.036 min−1, mean Kep values between 0.729 ± 0.112 min−1 and 2.299 ± 1.312 min−1, and mean Ve values between 0.1439 ± 0.093 and 0.272 ± 0.013. For MTs, mean Ktrans values varied from 0.130± 0.035 min−1 to 0.327 ± 0.030 min−1; mean Kep values from 0.463 ± 0.103 min−1 to 0.784 ± 0.064 min−1; and mean Ve values from 0.264 ± 0.119 to 0.445 ± 0.025. In all of these studies in the literature, the Ktrans values of PMAs were lower than those of other SGTs[3,14,15,28]. Xu et al[3] found that the mean Ktrans value of PMAs was slightly different from that of WTs (P = 0.05). Yabuuchi et al[14] found no significant differences among Ktrans values of other SGTs. Huang et al[15] found that the Ktrans values of PMAs were significantly lower than those of other SGTs. Similar to the results of Yabuuchi et al[14], in our study, mean Ktrans value of PMAs was the lowest among all SGTs, but it was not significantly different from those of other tumors. In the studies by Xu et al[3], Yabuuchi et al[14], and Huang et al[15], the mean Kep value was the lowest in PMAs and highest in WTs. Kep values of PMAs, WTs, and MTs in the studies of both Xu et al[3] and Yabuuchi et al[14] were significantly different. However, in the study by Huang et al[15], the Kep value of only WTs was significantly different from those of other tumors. In another study by Huang et al[28], significant differences were found in Kep values between WTs and PMAs, and between WTs and OBTs. Similar to the results of those studies in the literature, the mean Kep value in the present study was the lowest in PMAs and highest in WTs, and Kep values of PMAs and WTs were significantly different from those of other tumors[3,13,14,28]. Xu et al[3], Yabuuchi et al[14], and Huang et al[15] found that mean Ve values of WTs were significantly lower than those of other tumors. Similar to the results of their studies, the mean Ve value of WTs in the present study was significantly lower than those of other tumors[3,14]. In another study by Huang et al[28], unlike other studies, the Ve value of WTs and the Ve values of PMAs and OBTs were found to be significantly lower. In ROC analysis using a cut-off value of Kep ≥ 2.44 min−1 for WTs, the AUC, sensitivity, and specificity were 97.3%, 100%, and 85.5%, respectively. On the other hand, in ROC analysis using a cut-off value of Ve ≤ 0.17, quite high AUC, sensitivity, and specificity values (95.8%, 100%, and 90.9%, respectively) were obtained. High Kep and low Ve values in WTs are explained by the limited extravascular and extracellular space in these tumors. As many studies in the literature and the present study revealed, ADC and TIC patterns of WTs could overlap with those of MTs[11]. However, similar to the findings of the studies in the literature, the present study showed that quantitative perfusion MRI parameters Kep and Ve could contribute greatly to distinguishing WTs from MTs[3,14,15]. Nevertheless, our findings need to be verified by future quantitative perfusion MRI studies performed with larger series.
There are some limitations in this study. First, the parameters (number of dynamic series, acquisition time, etc.) varied on perfusion MRI series due to the retrospective nature of the study. Second, most of the tumors in our study were benign SGTs, and the number of MTs in the primary salivary gland was relatively low, which may have resulted in an overestimation of the diagnostic accuracy. Third, the manual definition of ROI might have increased the variability in quantitative measurements. Although the cystic-necrotic components of the lesions were excluded from the ROI in our study, contamination of these areas can lead to significant changes in quantitative values, even if it is small in manual measurements. Fourth, for the measurements of ADC values and semiquantitative and quantitative DCE perfusion MRI parameters, interobserver agreement could not be evaluated in the study as the measurements were made by two observers with consensus.
Combined use of quantitative DCE MRI along with diffusion MRI and semiquantitative DCE MRI could help radiologists in the differential diagnosis of different subtypes of SGTs by providing higher diagnostic accuracy.
Conventional magnetic resonance imaging (MRI) provides more data than other radiological modalities in determining the extent of tumor spread in salivary gland tumors (SGTs) and assessing its relationship to vascular and neural structures, but falls short of distinguishing subtypes of SGTs. As the malignant or benign nature of SGTs affects the treatment protocol, it is important to differentiate between malignant (MTs) and benign tumors (BTs) noninvasively with high diagnostic accuracy.
In recent years, advanced MRI techniques such as diffusion-weighted imaging (DWI) and semi-quantitative MRI have been increasingly used in the radiological evaluation of SGTs. However, various studies on quantitative dynamic contrast-enhanced (DCE) perfusion MRI parameters (Ktrans, Kep, and Ve) in SGTs are limited. Therefore, in this study, the effectiveness of advanced MRI applications, including all three methods, in the diagnosis of SGTs was evaluated in light of the literature.
To determine the diagnostic efficiency of DWI and DCE (semiquantitative perfusion) MRI and quantitative perfusion MRI parameters in SGTs.
Apparent diffusion coefficient (ADC) values of SGTs on DWI were measured with manually inserted regions of interest, excluding the cystic components of the tumors. Time intensity curve (TIC) patterns were created for semiquantitative perfusion MRI based on Tpeak and washout ratios (WRs) of tumors. On quantitative DCE MRI, perfusion parameters such as Ktrans [volume transfer constant between blood plasma and extracellular extravascular space (EES)], Kep (flux rate constant between the EES and plasma), and Ve (EES fractional volume) were used.
The ADC values of pleomorphic adenomas (PMAs) were significantly higher than those of Warthin's tumors (WTs), other benign tumors (OBTs), and MTs (P < 0.001). However, there was no significant difference in ADC values for OBTs, WTs, and MTs. PMAs had type A and WTs had type B TIC pattern while the vast majority of MTs and OBTs (54.5% and 45.5%, respectively) displayed type C TIC pattern. PMAs showed no washout, while the highest mean WR was observed in WTs. For quantitative perfusion MRI parameters, the Kep value of WTs was significantly higher than those of other tumors (P < 0.001). For the Ve value, WTs and OBTs differed significantly from PMAs and MTs (P < 0.001). Ktrans values of PMAs, WTs, OBTs, and MTs were not significantly different.
DWI and semiquantitative and quantitative perfusion MRI, which provide more information on the microstructure, cellularity, interstitial distance, and vascularity of tumors, have increased the discrimination power for subtypes of SGTs.
Although there is some overlap in the findings of the subtypes of SGTs obtained by advanced MRI methods, the combined use of DWI and semiquantitative and quantitative perfusion MRI will increase the power for distinguishing subtypes of SGTs.
We thank Demir O and Gürpınar AB for their help with the statistical analyses.
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Radiology, nuclear medicine and medical imaging
Country/Territory of origin: Turkey
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Li T, China; Ma C, China S-Editor: Liu XF L-Editor: Wang TQ P-Editor: Liu XF
1. | Gökçe E. Multiparametric Magnetic Resonance Imaging for the Diagnosis and Differential Diagnosis of Parotid Gland Tumors. J Magn Reson Imaging. 2020;52:11-32. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis (0)] |
2. | Lobo R, Hawk J, Srinivasan A. A Review of Salivary Gland Malignancies: Common Histologic Types, Anatomic Considerations, and Imaging Strategies. Neuroimaging Clin N Am. 2018;28:171-182. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
3. | Xu Z, Zheng S, Pan A, Cheng X, Gao M. A multiparametric analysis based on DCE-MRI to improve the accuracy of parotid tumor discrimination. Eur J Nucl Med Mol Imaging. 2019;46:2228-2234. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis (0)] |
4. | Zheng N, Li R, Liu W, Shao S, Jiang S. The diagnostic value of combining conventional, diffusion-weighted imaging and dynamic contrast-enhanced MRI for salivary gland tumors. Br J Radiol. 2018;91:20170707. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
5. | Yabuuchi H, Fukuya T, Tajima T, Hachitanda Y, Tomita K, Koga M. Salivary gland tumors: Diagnostic value of gadolinium-enhanced dynamic MR imaging with histopathologic correlation. Radiology. 2003;226:345-354. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 234] [Cited by in F6Publishing: 223] [Article Influence: 10.6] [Reference Citation Analysis (0)] |
6. | Lechner Goyault J, Riehm S, Neuville A, Gentine A, Veillon F. Interest of diffusion-weighted and gadolinium-enhanced dynamic MR sequences for the diagnosis of parotid gland tumors. J Neuroradiol. 2011;38:77-89. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
7. | Abdel Razek AA, Samir S, Ashmalla GA. Characterization of Parotid Tumors With Dynamic Susceptibility Contrast Perfusion-Weighted Magnetic Resonance Imaging and Diffusion-Weighted MR Imaging. J Comput Assist Tomogr. 2017;41:131-136. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 67] [Cited by in F6Publishing: 77] [Article Influence: 11.0] [Reference Citation Analysis (0)] |
8. | Yuan Y, Tang W, Tao X. Parotid gland lesions: Separate and combined diagnostic value of conventional MRI, diffusion-weighted imaging and dynamic contrast-enhanced MRI. Br J Radiol. 2016;89:20150912. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis (0)] |
9. | Mikaszewski B, Markiet K, Smugała A, Stodulski D, Szurowska E, Stankiewicz C. Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging-An Alternative to Fine Needle Biopsy or Only an Adjunct Test in Preoperative Differential Diagnostics of Malignant and Benign Parotid Tumors? J Oral Maxillofac Surg. 2017;75:2248-2253. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis (0)] |
10. | Yabuuchi H, Matsuo Y, Kamitani T, Setoguchi T, Okafuji T, Soeda H, Sakai S, Hatakenaka M, Nakashima T, Oda Y, Honda H. Parotid gland tumors: Can addition of diffusion-weighted MR imaging to dynamic contrast-enhanced MR imaging improve diagnostic accuracy in characterization? Radiology. 2008;249:909-916. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 182] [Cited by in F6Publishing: 199] [Article Influence: 12.4] [Reference Citation Analysis (0)] |
11. | Gökçe E, Beyhan M. Advanced magnetic resonance imaging findings in salivary gland tumors. World J Radiol. 2022;14:256-271. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis (2)] |
12. | Eida S, Sumi M, Nakamura T. Multiparametric magnetic resonance imaging for the differentiation between benign and malignant salivary gland tumors. J Magn Reson Imaging. 2010;31:673-679. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis (0)] |
13. | Munhoz L, Ramos EADA, Im DC, Hisatomi M, Yanagi Y, Asaumi J, Arita ES. Application of diffusion-weighted magnetic resonance imaging in the diagnosis of salivary gland diseases: A systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128:280-310. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
14. | Yabuuchi H, Kamitani T, Sagiyama K, Yamasaki Y, Hida T, Matsuura Y, Hino T, Murayama Y, Yasumatsu R, Yamamoto H. Characterization of parotid gland tumors: Added value of permeability MR imaging to DWI and DCE-MRI. Eur Radiol. 2020;30:6402-6412. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis (0)] |
15. | Huang N, Xiao Z, Chen Y, She D, Guo W, Yang X, Chen Q, Cao D, Chen T. Quantitative dynamic contrast-enhanced MRI and readout segmentation of long variable echo-trains diffusion-weighted imaging in differentiating parotid gland tumors. Neuroradiology. 2021;63:1709-1719. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
16. | Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-232. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 23] [Reference Citation Analysis (0)] |
17. | Celebi I, Mahmutoglu AS, Ucgul A, Ulusay SM, Basak T, Basak M. Quantitative diffusion-weighted magnetic resonance imaging in the evaluation of parotid gland masses: A study with histopathological correlation. Clin Imaging. 2013;37:232-238. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis (0)] |
18. | Assili S, Fathi Kazerooni A, Aghaghazvini L, Saligheh Rad HR, Pirayesh Islamian J. Dynamic Contrast Magnetic Resonance Imaging (DCE-MRI) and Diffusion Weighted MR Imaging (DWI) for Differentiation between Benign and Malignant Salivary Gland Tumors. J Biomed Phys Eng. 2015;5:157-168. [PubMed] [Cited in This Article: ] |
19. | Milad P, Elbegiermy M, Shokry T, Mahmoud H, Kamal I, Taha MS, Keriakos N. The added value of pretreatment DW MRI in characterization of salivary glands pathologies. Am J Otolaryngol. 2017;38:13-20. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
20. | Tao X, Yang G, Wang P, Wu Y, Zhu W, Shi H, Gong X, Gao W, Yu Q. The value of combining conventional, diffusion-weighted and dynamic contrast-enhanced MR imaging for the diagnosis of parotid gland tumours. Dentomaxillofac Radiol. 2017;46:20160434. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
21. | Eida S, Sumi M, Sakihama N, Takahashi H, Nakamura T. Apparent diffusion coefficient mapping of salivary gland tumors: Prediction of the benignancy and malignancy. AJNR Am J Neuroradiol. 2007;28:116-121. [PubMed] [Cited in This Article: ] |
22. | Elmokadem AH, Abdel Khalek AM, Abdel Wahab RM, Tharwat N, Gaballa GM, Elata MA, Amer T. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging for Differentiation Between Parotid Neoplasms. Can Assoc Radiol J. 2019;70:264-272. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis (0)] |
23. | Habermann CR, Arndt C, Graessner J, Diestel L, Petersen KU, Reitmeier F, Ussmueller JO, Adam G, Jaehne M. Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: Is a prediction of different histologic subtypes possible? AJNR Am J Neuroradiol. 2009;30:591-596. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 167] [Cited by in F6Publishing: 167] [Article Influence: 11.1] [Reference Citation Analysis (0)] |
24. | Faheem MH, Shady S, Refaat MM. Role of magnetic resonance imaging (MRI) including diffusion weighted images (DWIs) in assessment of parotid gland masses with histopathological correlation. Egypt J Radiol Nucl Med. 2018;49:368-373. [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
25. | Ogawa T, Kojima I, Ishii R, Sakamoto M, Murata T, Suzuki T, Kato K, Nakanome A, Ohkoshi A, Ishida E, Kakehata S, Shiga K, Katori Y. Clinical utility of dynamic-enhanced MRI in salivary gland tumors: Retrospective study and literature review. Eur Arch Otorhinolaryngol. 2018;275:1613-1621. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
26. | Lam PD, Kuribayashi A, Imaizumi A, Sakamoto J, Sumi Y, Yoshino N, Kurabayashi T. Differentiating benign and malignant salivary gland tumours: Diagnostic criteria and the accuracy of dynamic contrast-enhanced MRI with high temporal resolution. Br J Radiol. 2015;88:20140685. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
27. | Abdel Razek AAK, Mukherji SK. State-of-the-Art Imaging of Salivary Gland Tumors. Neuroimaging Clin N Am. 2018;28:303-317. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 9.8] [Reference Citation Analysis (0)] |
28. | Huang N, Chen Y, She D, Xing Z, Chen T, Cao D. Diffusion kurtosis imaging and dynamic contrast-enhanced MRI for the differentiation of parotid gland tumors. Eur Radiol. 2022;32:2748-2759. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis (0)] |